Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00507130 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00507130: Completed Phase 2 study, sponsored by MedImmune.
NCT00507130 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00507130, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.
Primary Outcome
Number of participants experiencing adverse events (includes both adverse events and serious adverse events)
Interventions
- OTHER PLACEBO
- BIOLOGICAL MEDI528 0.3 mg/kg
- BIOLOGICAL MEDI528 1 mg/kg
- BIOLOGICAL MEDI528 3 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
What the finished NCT00507130 record still lists
NCT00507130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 4 interventions - of which PLACEBO is the first listed.
NCT00507130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00507130 about?
NCT00507130 is a clinical study titled "A Study to Evaluate the Safety and Tolerability of the Administration of MEDI-528 When Administered in Multiple Doses to Adults With Mild Persistent Asthma". The primary objective of this study is to evaluate the safety and tolerability of escalating multiple SC doses of MEDI-528 in adult patients with mild persistent asthma.
What is the current status of trial NCT00507130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2007-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT00507130?
The interventions under investigation include: PLACEBO (OTHER), MEDI528 0.3 mg/kg (BIOLOGICAL), MEDI528 1 mg/kg (BIOLOGICAL), MEDI528 3 mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00507130?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00507130's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia